蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1258|回复: 0
收起左侧

[申报注册] 法国药监公布TXCELL的检查缺陷

[复制链接]
药生
发表于 2015-8-27 08:56:14 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
In June, TxCell has shut down theirmanufacturing facility in Besan?on, but the reason was not published. The sitemanufactures aseptically prepared small volume liquids. The products arepersonalized T cellimmunotherapies using antigen specific regulatory T-cells(Ag-Tregs) for severe chronic inflammatory and autoimmune diseases.
在6月,TXCELL关闭了其在BESANCON的生产工厂,但关闭原因并没有公布。该工厂生产无菌小容量注射液。药品为使用抗原T细胞(AG-TREGS)的个性化T细胞免疫疗法,用于严重慢性炎症和自身免疫疾病。
Now, the French National Agency for Medicines and HealthProducts Safety (ANSM) released the inspection report. The ANSM summarized thenature of non-compliance as follows:
日前法国药监(ANSM)公布了检查报告,其中汇总了不符合项如下:
"Overall, 22 deficiencies were observed,including 7 major deficiencies on the following topics:
共发现22项缺陷,其中7个为主要缺陷,是关于以下主题的:
1. The pharmaceutical quality system was deficient asseveral deviations opened during the period 2014-2015 were overdue and stillpending. Namely, 43 non conformities were related to environmental deviationsof which 30 were related to mould contamination during production ofinvestigational batches and Media Process Test. Moreover, some investigationalproduct batches were released whereas deviations cases were still open.
药品质量体系有缺陷,2014-2015年期间有多个偏差未关闭。换句话说,43项与环境偏差有关的不符合结果,其中30个与临床前批次和培养基工艺测试的生产过程中的霉菌污染有关。另外,有些临床前批次在偏差还未关闭时即已放行。
2. Paper batch records and labels required in asepticareas were not sterilised or passed into the area by a procedure which achievesthe same objective of not introducing contamination.
无菌区域的纸质批记录和标签未灭菌,或通过控制程序传递进入无菌区来保证不引入污染。
3. Appropriate alert limits were not set for the resultsof microbiological monitoring of clean rooms."
洁净区微生物监测结果没有设定适当的警戒限。
TXCells is currently working on improvements of the pilotsite and expects to complete the necessary activities and to get reapproveduntil end of 2015. In the meantime, the manufacturing of the clinical batcheswas outsourced to a CMO.
EXCELLS现在正在努力改善其中试工厂状况,期望能完成必要的措施,到2015年底重新获得批准。其临床批次的生产已外包给一个CMO。
More details can be found in the ANSM report as well as in the TxCell press release.
更多信息可以在上述ANSM官网和TXCELL新闻网站找到。
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-6-13 00:06

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表